Skip to main content

Posters

November 22, 2019
Purpose: Sleep disturbances are associated with attention-deficit/hyperactivity disorder (ADHD) and methylphenidate (MPH) treatment. We assessed whether sleep-related adverse event (AE) rates are affected by sample and study design features of trials evaluating MPH in youth with ADHD.
November 22, 2019
Background: Depression is commonly comorbid with narcolepsy and obstructive sleep apnea (OSA). Solriamfetol (SunosiTM), a dopamine/norepinephrine reuptake inhibitor, has been approved in the US to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy (75-…
November 22, 2019
Background: Solriamfetol (formerly JZP-110), a dopamine and norepinephrine reuptake inhibitor, has been approved in the US (SunosiTM) to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy (75-150mg/d) or obstructive sleep apnea (OSA [37.5-150mg/d]).…
March 02, 2019
Background: Narcolepsy diagnosis can be challenging. Presence of comorbidities and overlapping symptoms between narcolepsy and other conditions may contribute to diagnostic delay and misdiagnosis. Objective: To describe the frequency of misdiagnoses and comorbidities in participants diagnosed with…
March 02, 2019
Background: Sleep problems are common in adults with attention-deficit/hyperactivity disorder (ADHD). This study examined the effect of baseline sleep quality on response to treatment with SHP465 mixed amphetamine salts (MAS) extended-release.
March 02, 2019
INTRODUCTION: Solriamfetol, a selective dopamine/norepinephrine reuptake inhibitor, significantly decreased excessive sleepiness in a randomized, double-blind, placebo-controlled study of adults with narcolepsy. Health-related quality of life (HRQoL) results (secondary endpoints) are reported here.
March 02, 2019
INTRODUCTION: Excessive sleepiness (ES) is a prominent symptom of narcolepsy and obstructive sleep apnea (OSA). Solriamfetol, a selective dopamine/norepinephrine reuptake inhibitor, was effective in treating ES in narcolepsy and OSA in phase 3 studies. This study evaluated the long-term safety and…
March 02, 2019
Introduction: Narcolepsy primarily begins in childhood/adolescence. Sodium oxybate (SXB) was evaluated as a treatment for narcolepsy in children/adolescents in a placebo-controlled, randomized-withdrawal study with open-label extension (OLE). The long-term evaluation of depression, anxiety, and…
March 02, 2019
Objective: To evaluate the long-term efficacy and safety of sodium oxybate (SXB) treatment for narcolepsy in pediatric patients in a placebo-controlled, randomized-withdrawal study with an open-label evaluation.
March 02, 2019
Objective: To evaluate the long-term efficacy and safety of sodium oxybate (SXB) treatment for narcolepsy in pediatric patients in a placebo-controlled, randomized-withdrawal study with an open-label evaluation.
Back to Top